{
    "clinical_study": {
        "@rank": "143116", 
        "arm_group": [
            {
                "arm_group_label": "Insulin peglispro (with Insulin Lispro)", 
                "arm_group_type": "Experimental", 
                "description": "Insulin preglispro once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required"
            }, 
            {
                "arm_group_label": "Insulin Glargine (with Insulin Lispro)", 
                "arm_group_type": "Active Comparator", 
                "description": "Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will look into how a base dose of insulin peglispro and insulin glargine will\n      affect the meal time dose and efficacy of insulin lispro in type 1 diabetics. This study is\n      expected to last up to 17 weeks."
        }, 
        "brief_title": "A Study to Compare and Measure the Effects of Insulin Peglispro and Glargine on Meal Time Insulin Requirements", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a stable (within 0.5 percent (%) from last measure) glycated hemoglobin (HbA1c)\n             <9.0%\n\n          -  Have a stable (within 30%) basal insulin dose of 0.2 to 1.0 units per kilogram per\n             day (U/kg/day) and a total daily insulin dose (basal + prandial/bolus) <1.5 units per\n             kilogram (U/kg)\n\n          -  Have C-peptide <0.3 nanomoles per liter (nmol/L)\n\n          -  Are able and willing to eat the protocol specified standard breakfast and other meals\n             as required\n\n        Exclusion Criteria:\n\n          -  Have corrected QT interval (QTc) prolongation >500 milliseconds (ms) or have any\n             other abnormality in the 12 lead electrocardiogram (ECG) that, in the opinion of the\n             investigator, increases the risks associated with participating in the study\n\n          -  Have an abnormal blood pressure as determined by the investigator\n\n          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,\n             gastrointestinal, endocrine (apart from Type 1 Diabetes Mellitus [T1DM]),\n             hematological, or neurological disorders\n\n          -  Have fasting triglycerides (TGs) >400 milligrams per deciliter (mg/dL) (4.52\n             micromoles per liter [mmol/L])\n\n          -  Have used systemic corticosteroids within 4 weeks prior to randomization\n\n          -  Currently receive insulin pump or insulin degludec\n\n          -  Have poorly controlled diabetes or are known to have poor awareness of hypoglycemia\n\n          -  Have history of gastroparesis or gastrointestinal malabsorption\n\n          -  Require treatment with any drug other than insulin to treat diabetes\n\n          -  Have a previous history of proliferative retinopathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152384", 
            "org_study_id": "15406", 
            "secondary_id": "I2R-MC-BIDU"
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin peglispro (with Insulin Lispro)", 
                "description": "Administered SC", 
                "intervention_name": "Insulin Peglispro", 
                "intervention_type": "Drug", 
                "other_name": "LY2605541"
            }, 
            {
                "arm_group_label": [
                    "Insulin peglispro (with Insulin Lispro)", 
                    "Insulin Glargine (with Insulin Lispro)"
                ], 
                "description": "Administered SC", 
                "intervention_name": "Insulin Lispro", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin Glargine (with Insulin Lispro)", 
                "description": "Administered SC", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on the Dose Response Effect of Prandial Insulin Lispro in Patients With Type 1 Diabetes Mellitus.", 
        "overall_contact": {
            "last_name": "This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacodynamics: Plasma Glucose Area Under the Concentration Curve (AUC), Above Pre Meal Baseline for Insulin Lispro", 
            "safety_issue": "No", 
            "time_frame": "Day 30 through Day 34 of study insulin dosing, predose through 5 hours postdose of insulin lispro"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152384"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) for Prandial Insulin Lispro", 
                "safety_issue": "No", 
                "time_frame": "Day 29, predose through 5 hours postdose"
            }, 
            {
                "measure": "Pharmacodynamics: Average Glucose Infusion Rate from Euglycemic 2-step Hyperinsulinemic Clamp (M-value)", 
                "safety_issue": "No", 
                "time_frame": "Day 35, last 60 minutes (final step) of euglycemic 2-step hyperinsuinemic clamp"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) for Paracetamol", 
                "safety_issue": "No", 
                "time_frame": "Day 29, predose through 5 hours postdose"
            }, 
            {
                "measure": "Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "Days 29 through 34, pre-breakfast through 5 hours post breakfast"
            }, 
            {
                "measure": "Pharmacodynamics: Area Under the Concentration Curve for Triglyceride", 
                "safety_issue": "No", 
                "time_frame": "Day 29, predose through 5 hours postdose"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp", 
                "safety_issue": "No", 
                "time_frame": "Day 35, insulin clearance during lispro infusion"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}